Premium
Endocan Elicits Severe Vascular Inflammatory Responses In Vitro and In Vivo
Author(s) -
Lee Wonhwa,
Ku SaeKwang,
Kim ShinWoo,
Bae JongSup
Publication year - 2014
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.24485
Subject(s) - proinflammatory cytokine , umbilical vein , sepsis , lipopolysaccharide , medicine , neutralizing antibody , cxcl1 , in vivo , antibody , immunology , tumor necrosis factor alpha , inflammation , pharmacology , in vitro , chemokine , chemistry , biology , biochemistry , microbiology and biotechnology
Endocan is a proteoglycan secreted by endothelial cells under the control of inflammatory cytokines. The aim of this study was to evaluate the effects of endocan on proinflammatory responses and on septic mice and underlying mechanisms. Human umbilical vein endothelial cells (HUVECs) or mice were exposed to lipopolysaccharide (LPS) or endocan with or without neutralizing endocan antibody. Mice were subjected to cecal ligation and puncture (CLP) surgery with or without neutralizing endocan antibody. Endocan was highly released by LPS and it enhanced proinflammatory responses. In a CLP‐induced sepsis model, endocan was also highly released, but this release was prevented by administration of neutralizing endocan antibody. Circulating levels of endocan measured in patients admitted to the intensive care unit with sepsis were significantly elevated compared with control donors. Furthermore, the administration of endocan antibody reduced CLP‐induced sepsis mortality. This study shows endocan can elicit severe inflammatory responses and inhibiting endocan release offers a potential strategy for treating sepsis. J. Cell. Physiol. 229: 620–630, 2014. © 2013 Wiley Periodicals, Inc.